| Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics |
MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00368) against Liquidia alleging infringement of U.S. Patent No. 11,357,782 (the ‘782 patent). Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA™ (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). |
globenewswire.com |
2025-05-12 10:00:00 |
Czytaj oryginał (ang.) |
| Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript |
Liquidia Corporation (NASDAQ:LQDA ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Michael Kaseta - Chief Operating Officer and Chief Financial Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG, LLC Kambiz Yazdi - Jefferies Group LLC Greg Harrison - Scotiabank Cory Jubinville - LifeSci Capital Serge Belanger - Needham & Company, LLC Ryan Deschner - Raymond James Financial, Inc. Operator Good morning, and welcome everyone to the Liquidia Corporation First Quarter 2025 Financial Results and Corporate Update Conference Call. My name is Ari, and I will be your conference operator today. |
seekingalpha.com |
2025-05-11 01:29:49 |
Czytaj oryginał (ang.) |
| Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates |
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2025-05-08 12:45:37 |
Czytaj oryginał (ang.) |
| Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update |
MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will also host a webcast at 8:30 a.m. ET on May 8, 2025 to discuss its financial results and provide a corporate update. |
globenewswire.com |
2025-05-08 10:30:00 |
Czytaj oryginał (ang.) |
| Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month |
Liquidia Corporation's legal victory clears the path for Yutrepia's FDA approval and market entry, targeting PAH and PH-ILD, with final approval expected by May 24, 2025. Yutrepia's competitive advantages include a patient-friendly inhaler, lower cost structure, and strong clinical profile, positioning it to capture market share from United Therapeutics' Tyvaso DPI. Liquidia is financially prepared for Yutrepia's launch, boasting $176.5 million in cash and milestone financing, ensuring a smooth commercialization without diluting shareholders. |
seekingalpha.com |
2025-05-05 20:06:13 |
Czytaj oryginał (ang.) |
| Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains? |
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-05-05 14:50:40 |
Czytaj oryginał (ang.) |
| District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia |
MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Court) dismissed, without prejudice, the cross-claim filed by United Therapeutics (UTHR) that sought to challenge Liquidia's amendment to its New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder, which added the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) to the proposed label for YUTREPIA. In its ruling, the District Court determined that UTHR's claim was unripe and that UTHR had failed to plausibly allege that it has standing. |
globenewswire.com |
2025-05-02 21:28:00 |
Czytaj oryginał (ang.) |
| Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 |
MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. |
globenewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Arquitos Capital's Largest Holdings For Q1 2025 |
ENDI Corp's shares rose significantly, driven by a substantial increase in AUM and a value-unlocking transaction, suggesting further upside potential. Finch Therapeutics awaits a post-trial decision that could significantly impact its share value, with a minimum award level already set. Nam Tai Property secured significant financing and sold a non-core property above appraisal value, indicating a potential closing of the gap between market price and fair value. |
seekingalpha.com |
2025-04-30 13:30:00 |
Czytaj oryginał (ang.) |
| UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference |
Liquidia Corporation will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. |
globenewswire.com |
2025-04-01 14:33:00 |
Czytaj oryginał (ang.) |
| Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference |
Liquidia Corporation will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. |
globenewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder |
The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder. |
globenewswire.com |
2025-03-28 11:30:00 |
Czytaj oryginał (ang.) |
| Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript |
Liquidia Corporation (NASDAQ:LQDA ) Q4 2024 Earnings Conference Call March 19, 2025 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - CEO Michael Kaseta - COO and CFO Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Rusty Schundler - General Counsel Conference Call Participants Julian Harrison - BTIG Serge Belanger - Needham Ryan Deschner - Raymond James Greg Harrison - Scotiabank Cory Jubinville - LifeSci Capital Operator Good morning. And welcome everyone to Liquidia Corporation Full Year 2024 Financial Results and Corporate Update Conference Call. |
seekingalpha.com |
2025-03-19 13:56:06 |
Czytaj oryginał (ang.) |
| Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates |
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.42 per share a year ago. |
zacks.com |
2025-03-19 10:45:21 |
Czytaj oryginał (ang.) |
| Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update |
Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty Partners (HCRx) Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C. |
globenewswire.com |
2025-03-19 08:30:00 |
Czytaj oryginał (ang.) |
| Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 |
MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. |
globenewswire.com |
2025-03-12 10:00:00 |
Czytaj oryginał (ang.) |
| Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last? |
Liquidia Technologies (LQDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-01-22 12:15:27 |
Czytaj oryginał (ang.) |
| Liquidia named a top pick for 2025 at Needham |
Needham analyst Serge Belanger named Liquidia a top pick for 2025 with a Buy rating and $19 price target. The stock was also the analyst's top pick for 2024, and "disappointed" with a negative 2% performance mostly due to the mid-August setback when the FDA delayed approval by retroactively granting Tyvaso DPI a three year exclusivity dating to 2022, Needham points out. The firm says its "investment thesis is stronger now than a year ago." It has a "clear line of sight" for FDA approval of Yutrepia in both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease by May 23. Yutrepia will launch into an opportunity that will have grown into a $2B market by mid-2025, on its way to over $3B-$4B by 2030, contends the firm. |
https://thefly.com |
2025-01-09 12:14:00 |
Czytaj oryginał (ang.) |
| Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Liquidia Technologies (LQDA) points to a 132.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-12-12 12:55:19 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High? |
The consensus price target hints at a 126.1% upside potential for Liquidia Technologies (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-26 12:55:14 |
Czytaj oryginał (ang.) |
| Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off |
Liquidia's Yutrepia, a competitor to United Therapeutics' Tyvaso, faces potential market entry in 2025, with promising clinical data and a competitive therapeutic profile. Despite financial challenges and intense competition, Liquidia's low valuation and upcoming product launches present a compelling investment opportunity. Liquidia's legal battles with United Therapeutics are nearing resolution, potentially clearing the path for Yutrepia's commercial launch by mid-2025. |
seekingalpha.com |
2024-11-15 12:20:08 |
Czytaj oryginał (ang.) |
| Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript |
Liquidia Corporation (NASDAQ:LQDA ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Michael Kaseta - Chief Operating Officer & Chief Financial Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG Jason Gerberry - Bank of America Greg Harrison - Scotiabank Kambiz Yazdi - Jefferies Cory Jubinville - LifeSci Capital Matt Kaplan - Ladenburg Thalmann Ryan Deschner - Raymond James Operator Good morning and welcome everyone to Liquidia Corporation Third Quarter 2024 Financial Results and Corporate Update Conference Call. My name is Michelle [ph] and I will be your conference operator today. |
seekingalpha.com |
2024-11-13 16:40:22 |
Czytaj oryginał (ang.) |
| Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates |
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.37 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2024-11-13 10:40:26 |
Czytaj oryginał (ang.) |
| Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appeal Strengthened balance sheet by raising approximately $100 million in additional capital MORRISVILLE, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-11-13 08:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-04 20:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-11-02 13:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-01 00:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-10-29 14:00:00 |
Czytaj oryginał (ang.) |
| Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release |
Liquidia Technologies (LQDA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-29 13:06:27 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-10-27 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-10-25 21:52:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-10-23 22:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-10-21 20:45:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-10-19 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-10-18 01:43:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-10-16 00:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-10-13 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA |
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-10-11 21:00:00 |
Czytaj oryginał (ang.) |